Patents by Inventor Christopher U. Missling

Christopher U. Missling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12285403
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Grant
    Filed: October 9, 2023
    Date of Patent: April 29, 2025
    Assignee: Anavex Life Sciences, Corp.
    Inventor: Christopher U. Missling
  • Patent number: 12280034
    Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: April 22, 2025
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Publication number: 20250115566
    Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. The present disclosure provides pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
    Type: Application
    Filed: December 17, 2024
    Publication date: April 10, 2025
    Inventors: Christopher U. Missling, Alani Selvey
  • Publication number: 20250064772
    Abstract: A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.
    Type: Application
    Filed: November 8, 2024
    Publication date: February 27, 2025
    Applicant: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Patent number: 12180174
    Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: December 31, 2024
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Alani Selvey
  • Publication number: 20240417798
    Abstract: The present disclosure provides methods for individualized selection of, and monitoring of treatment using a neurodegenerative therapeutic agent such as Sigma-1 receptor agonist therapy for a subject, based on changes in gene expression pre- and post-treatment. The present disclosure also provides methods to evaluate current status or risk of a subject in developing neurodegenerative disorders. Also provided are kits for practicing the methods.
    Type: Application
    Filed: November 23, 2022
    Publication date: December 19, 2024
    Inventor: Christopher U. Missling
  • Patent number: 12138240
    Abstract: A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: November 12, 2024
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Publication number: 20240156810
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Application
    Filed: January 18, 2024
    Publication date: May 16, 2024
    Inventor: Christopher U. Missling
  • Publication number: 20240066003
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Application
    Filed: October 30, 2023
    Publication date: February 29, 2024
    Applicant: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Patent number: 11896590
    Abstract: A method for the treatment and/or prevention of pain which comprises administering to a subject in need of such treatment a therapeutically effective amount of 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and pharmaceutically acceptable salts thereof (“AV1066”), with reference to visceral and neuropathic pain.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: February 13, 2024
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • Publication number: 20240041818
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 8, 2024
    Inventor: Christopher U. Missling
  • Patent number: 11839600
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 12, 2023
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Patent number: 11813242
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: November 14, 2023
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Publication number: 20230301961
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 28, 2023
    Applicant: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Patent number: 11690821
    Abstract: This invention concerns a dosage form comprising a therapeutically effective amount of A19-144 or A2-73 and a therapeutically effective amount of at least one AED. This invention further encompasses a method of treating a subject in need of such treatment comprising administering a therapeutically effective amount of A19-144 or A2-73 in conjunction with any therapeutically effective amount of an AED.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: July 4, 2023
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Cameron Durrant
  • Patent number: 11622955
    Abstract: A method for lowering systolic blood pressure in a patient exhibiting resistance to a antihypertensive therapy with one or more drugs, the method comprising administering to the patient ANAVEX®2-73 at a dose and frequency effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, 24-hour ambulatory systolic, and maximum diurnal systolic blood pressures.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: April 11, 2023
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling
  • Publication number: 20220387373
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Application
    Filed: August 17, 2022
    Publication date: December 8, 2022
    Inventor: Christopher U. Missling
  • Patent number: 11498908
    Abstract: The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: November 15, 2022
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventors: Christopher U. Missling, Alani Selvey
  • Publication number: 20220347149
    Abstract: A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.
    Type: Application
    Filed: May 23, 2022
    Publication date: November 3, 2022
    Inventor: Christopher U. Missling
  • Patent number: 11446275
    Abstract: This invention addresses tetrahydro-N, N-dimethyl-2,2diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: September 20, 2022
    Assignee: ANAVEX LIFE SCIENCES CORP.
    Inventor: Christopher U. Missling